PT-141 10mg (10 vials/kit): Central Melanocortin Receptor Agonist for Research

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone ($\alpha\text{-MSH}$) with the chemical sequence $\text{Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH}$. Functioning as a high-affinity agonist across central melanocortin receptor subtypes—specifically MC3R and MC4R—PT-141 acts directly within the central nervous system (CNS) to modulate hypothalamic signaling pathways governing sexual arousal, motivation, and cardiovascular dynamics. Sourcing PT-141 10mg (10 vials/kit) provides neuroscience laboratories, academic institutions, and preclinical researchers with a standardized, high-purity analytical reagent engineered to investigate central neuroendocrine circuits without relying on peripheral vascular mechanisms.

In neurobiological and physiological research, PT-141 is distinguished by its central mechanism of action. Unlike traditional vasoactive compounds that target peripheral phosphodiesterase-5 (PDE-5) pathways or smooth muscle relaxation, PT-141 crosses the blood-brain barrier to bind MC3 and MC4 receptors in the medial preoptic area (mPOA) and hypothalamus. This central activation triggers downstream dopamine and oxytocin neurotransmission, driving behavioral arousal responses in preclinical models. Utilizing the standardized PT-141 10mg (10 vials/kit) format ensures reliable receptor binding kinetics and precise dose-response profiling across behavioral and neuroendocrine bioassays.

Maintaining strict analytical purity and multi-vial stability is essential for quantitative behavioral and physiological assays. The PT-141 10mg (10 vials/kit) configuration delivers a total yield of 100mg active material distributed across ten individual 10mg USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This modular multi-vial system allows laboratory personnel to reconstitute only the working volume required for immediate experimental protocols, keeping remaining kit stock preserved in deep freeze stasis and avoiding structural loss caused by repeated freeze-thaw cycles.

Receptor Agonism, Neuroendocrine Signaling, and Technical Profile of PT-141

The primary research value of PT-141 10mg (10 vials/kit) stems from its potent cyclic structure and central receptor interaction profile:

• Central MC3R & MC4R Agonism: Binds central melanocortin receptors MC3R and MC4R with nanomolar affinity, modulating neuroendocrine circuits in the hypothalamus to drive motivation and arousal pathways.

• Non-Vascular Mechanism: Operates independently of the nitric oxide/cGMP pathway, avoiding direct peripheral vasodilation and offering a unique CNS-driven model for physiological research.

• Dopaminergic & Oxytocinergic Integration: Stimulates localized dopamine release in the nucleus accumbens and prefrontal cortex, supporting research into central reward and social/behavioral dynamics.

• Cyclic Structural Stability: Internal side-chain lactam bridge ($\text{Asp-Lys}$) provides high resistance against enzymatic cleavage by tissue proteases compared to linear peptides.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis (SPPS) and purified using preparative High-Performance Liquid Chromatography (HPLC) to guarantee complete removal of truncated fragments and residual reagents.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with PT-141 10mg (10 vials/kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Equilibration: Allow the frozen PT-141 10mg (10 vials/kit) vial to adjust to ambient room temperature prior to solvent introduction to eliminate condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Sterile Water for Injection. Direct the stream against the inner glass wall so it trickles gently over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as turbulent agitation can shear peptide bonds and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted solution into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of PT-141 10mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm individual component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: PT-141 10mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. PT-141 10mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.